How many drugs treat Myelodysplastic syndrome?

Drug Landscape tracks 10 marketed treatments for Myelodysplastic syndrome (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/myelodysplastic-syndrome.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Myelodysplastic syndrome — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myelodysplastic syndrome (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myelodysplastic syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Inqovi	Inqovi	Otsuka	Nucleoside Metabolic Inhibitor [EPC]	Cytidine deaminase	2020-01-01
Reblozyl	LUSPATERCEPT	Celgene Corp	Erythroid Maturation Agent [EPC]	Growth/differentiation factor 11	2019-01-01
Dacogen	decitabine	Sun Pharma	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01
Revlimid	lenalidomide	Bristol-Myers Squibb	Thalidomide analogue	Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)	2005-01-01
Vidaza	azacitidine	Bristol-Myers Squibb	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2004-01-01
Revlimid	Revlimid	M.D. Anderson Cancer Center		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
azacytidine	azacytidine	Assistance Publique Hopitaux De Marseille		DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A
REBLOZYL	LUSPATERCEPT-AAMT	CELGENE CORP	Erythroid Maturation Agent [EPC]	Growth/differentiation factor 11, Growth/differentiation factor 8
Reblozyl	Reblozyl	EuroBloodNet Association		Growth/differentiation factor 11, Growth/differentiation factor 8
Lenali	Lenali	Singapore General Hospital		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 2 drugs in Myelodysplastic syndrome
CELGENE CORP · 1 drug in Myelodysplastic syndrome
Celgene Corp · 1 drug in Myelodysplastic syndrome
EuroBloodNet Association · 1 drug in Myelodysplastic syndrome
M.D. Anderson Cancer Center · 1 drug in Myelodysplastic syndrome
Mayo Clinic · 1 drug in Myelodysplastic syndrome
Otsuka · 1 drug in Myelodysplastic syndrome
Singapore General Hospital · 1 drug in Myelodysplastic syndrome
Assistance Publique Hopitaux De Marseille · 1 drug in Myelodysplastic syndrome
Sun Pharma · 1 drug in Myelodysplastic syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myelodysplastic syndrome:

Cite this brief

Drug Landscape (2026). Myelodysplastic syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myelodysplastic-syndrome. Accessed 2026-06-09.

Myelodysplastic syndrome full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing